Pear Therapeutics
Sanofi has found yet another partner to help digitize its clinical trial processes.
Although generations of Americans have struggled with opioid addiction, what was once seen as a peripheral drug problem has lately hit the American public with force.
Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding.
Boston and San Francisco-based Pear Therapeutics, not to be confused with Pear Sports, has raised an undisclosed sum in a round led by 5AM Ventures.